{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 43 of 128', 'The end of the trial is defined as the date of the last visit of the last subject in the trial', 'globally.', 'Final collection of data for the primary endpoint occurs at Week 16.', '7.4 Software', 'Clinical Data Interchange Standards Consortium (CDISC) controlled terminology version 30-', 'Mar-2018 or newer was used for definition of controlled terminology used throughout this', 'protocol and will be used for statistical programming and output. Study Data Tabulation', 'Model (SDTM) version 1.4 will be used for data tabulations and SDTM Implementation', 'Guide version 3.2 will be adhered to.', 'Dose-response modelling will be done using the package DoseFinding implemented in', 'R statistical software version 3.5.0 or newer. All other analysis will be performed using SAS', 'statistical software version 9.4.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 44 of 128', '8 Trial population', '8.1 Subject eligibility', 'The investigator should only include subjects who meet all eligibility criteria, are not put at', 'undue risk by participating in the trial and can be expected to comply with the protocol.', \"The subject's eligibility for the clinical trial must be verified according to the inclusion and\", 'exclusion criteria at visits specified in Panel 2. It will be recorded in the electronic case report', 'form (eCRF) if the subject has met all the inclusion criteria and none of the exclusion criteria.', \"Any implementation of national requirements/law for the subject's participation in the clinical\", 'trial will be ensured and described in submission documentation to regulatory authorities and', 'institutional review boards (IRBs) / independent ethics committees (IECs), as applicable.', '8.2 Inclusion criteria', 'For inclusion into this trial, subjects must fulfil all of the following criteria:', '1. Signed and dated informed consent has been obtained prior to any protocol-related', 'procedures.', '2. Age 18 years or above.', '3. Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for', 'more than 3 months or returned twice or more within the last 12 months.', '4.', \"Disease severity graded as mild to severe according to Investigator's Global\", 'Assessment (i.e., an IGA score of 2 or more).', '5. Recent history (within 1 year before the screening visit) of inadequate response to', 'topical corticosteroid treatment or topical corticosteroid treatment being medically', 'inadvisable.', '6. Diagnostic patch testing performed within 3 years prior to the screening visit.', '7. A woman of childbearing potential* must use a highly effective* form of birth', 'control throughout the trial and for at least 2 weeks after last application of IMP.', '*', 'A woman is defined as not being of childbearing potential if she is postmenopausal', '(at least 12 months with no menses without an alternative medical cause prior to', 'screening), or surgically sterile (hysterectomy, bilateral salpingectomy, or bilateral', 'oophorectomy).']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 45 of 128', '**A highly effective method of birth control is defined as one which results in a low', 'failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine', 'device, intrauterine hormone-releasing system, combined (estrogen and progestogen', 'containing) hormonal contraception associated with inhibition of ovulation (oral,', 'intravaginal, transdermal), progestogen-only hormonal contraception associated with', 'inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is', 'in line with the preferred and usual life style of the subject), vasectomised partner', '(given that the subject is monogamous).', '8.3 Exclusion criteria', 'Subjects must not enter the trial if any of the following exclusion criteria are fulfilled:', '1. Concurrent skin diseases on the hands, e.g. tinea manuum.', '2. Active atopic dermatitis in regions other than the hands or psoriasis requiring medical', 'treatment.', '3. Clinically significant infection (e.g., impetiginised hand eczema) on the hands.', '4. Systemic treatment with immunosuppressive drugs (e.g., methotrexate, cyclosporine,', 'azathioprine), immunomodulating drugs (e.g., janus kinase inhibitors), retinoids (e.g.,', 'alitretinoin), or corticosteroids within 4 weeks prior to baseline (inhaled or intranasal', 'steroids corresponding to up to 1 mg prednisolone for asthma or rhinitis may be used).', '5. Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within', '4 weeks prior to baseline.', '6. Receipt of live attenuated vaccines 4 weeks prior to baseline.', '7. Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4', '(PDE-4) inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands', 'within 2 weeks prior to baseline.', '8. Use of systemic antibiotics or cutaneously applied antibiotics on the hands within', '2 weeks prior to baseline.', '9. Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e.,', 'subjects must not start antihistamine treatment or change the current dosage regime', 'within 2 weeks prior to baseline.', \"10. Other cutaneously applied therapy on the hands (except for the use of subject's own\", 'emollients) within 1 week prior to baseline.']\n\n###\n\n", "completion": "END"}